Abstract
Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but resistance inevitably develops. Using metastatic samples from a prospective phase II clinical trial, we epigenetically profiled enhancer/promoter activities with H3K27ac chromatin immunoprecipitation followed by sequencing, before and after AR-targeted therapy. We identified a distinct subset of H3K27ac-differentially marked regions that associated with treatment responsiveness. These data were successfully validated in mCRPC patient-derived xenograft models (PDX). In silico analyses revealed HDAC3 as a critical factor that can drive resistance to hormonal interventions, which we validated in vitro. Using cell lines and mCRPC PDX tumors in vitro, we identified drug-drug synergy between enzalutamide and the pan-HDAC inhibitor vorinostat, providing therapeutic proof-of-concept. These findings demonstrate rationale for new therapeutic strategies using a combination of AR and HDAC inhibitors to improve patient outcome in advanced stages of mCRPC.
Competing Interest Statement
WZ and AMB received research funding from Astellas Pharma for the work performed in this manuscript. All other authors declare no competing interests.
Clinical Trial
NCT01855477
Funding Statement
This work is supported by Astellas Pharma Europe BV (WZ, AMB), The Prostate Cancer Foundation (Challenge Award - MLF, MMP, WZ, TMS); The United States Department of Defense (Idea Award, PC180367 - MLF, MMP, WZ); Oncode Institute (WZ), KWF Dutch Cancer Society / Alpe d'HuZes (10084 - WZ, AMB and 7080 - AMB, MSvdH, LW), PNW Prostate Cancer SPORE (P50CA097186, P01CA163227 - EC) and Craig Watjen Memorial funds (EC); Academy of Finland (#349314 - AU) and Norwegian Cancer Society (#198016-2018 - AU); S. H. and M.N. Academy of Finland (#312043, #310829).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the local medical ethics committee of the Netherlands Cancer Institute and was activated on January 24th, 2012.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* shared first authors
Data Availability
Raw ChIP-sequence data are deposited in the European Genome-Phenome Archive (EGAS00001006161).
